1. Home
  2. CULP vs ACET Comparison

CULP vs ACET Comparison

Compare CULP & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Culp Inc.

CULP

Culp Inc.

HOLD

Current Price

$3.63

Market Cap

52.7M

ML Signal

HOLD

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$0.47

Market Cap

93.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CULP
ACET
Founded
1972
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Textiles
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
52.7M
93.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CULP
ACET
Price
$3.63
$0.47
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$8.50
AVG Volume (30 Days)
38.7K
2.3M
Earning Date
12-10-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$204,919,000.00
N/A
Revenue This Year
$1.93
N/A
Revenue Next Year
$2.77
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.42
$0.45
52 Week High
$5.94
$1.11

Technical Indicators

Market Signals
Indicator
CULP
ACET
Relative Strength Index (RSI) 36.34 30.48
Support Level $3.60 $0.50
Resistance Level $3.82 $0.59
Average True Range (ATR) 0.15 0.04
MACD -0.01 -0.00
Stochastic Oscillator 5.26 4.67

Price Performance

Historical Comparison
CULP
ACET

About CULP Culp Inc.

Culp Inc manufactures, markets mattress fabrics for bedding and upholstery fabrics for residential, commercial, and hospitality furnishings. The company has two operating segments: Mattress fabrics, which generate maximum revenue, and Upholstery fabrics. The mattress fabrics segment manufactures, sources, and sells fabrics and mattress covers to bedding manufacturers. The upholstery fabrics segment develops, sources, manufactures, and sells fabrics to residential, commercial, and hospitality furniture manufacturers. Geographically, it derives key revenue from the United States of America.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: